Stock Expert AI

STXI (STXI) ETF Analysis

STXI is an index-tracking ETF providing exposure to a basket of global stocks. With holdings in just 10 companies, it offers a concentrated portfolio. The fund's top allocations include ASML Holding NV, Novartis AG, and Roche Holding AG.

As of 2026-03-15, STXI exhibits a dividend yield of 0.00% and a three-year beta of 0.00, indicating low volatility relative to the broader market. Past performance does not guarantee future results.

STXI (STXI) ETF — Price, Holdings & Analysis

STXI is an index-tracking ETF providing exposure to a basket of global stocks. With holdings in just 10 companies, it offers a concentrated portfolio. The fund's top allocations include ASML Holding NV, Novartis AG, and Roche Holding AG. As of 2026-03-15, STXI exhibits a dividend yield of 0.00% and a three-year beta of 0.00, indicating low volatility relative to the broader market. Past performance does not guarantee future results.

ETF Genel Bakış

STXI aims to replicate the performance of an index comprised of a small selection of global stocks. The ETF achieves this by investing in the constituent companies of the underlying index, weighting them according to their index representation. With only 10 holdings, STXI offers a concentrated approach to global equities, potentially leading to higher volatility compared to more diversified ETFs. The fund's top holdings include ASML Holding NV (2.94%), Novartis AG Registered Shares (1.77%), and Roche Holding AG (1.77%). Other significant allocations include HSBC Holdings PLC (1.71%) and AstraZeneca PLC (1.67%). This concentrated portfolio may appeal to investors seeking targeted exposure to specific global companies rather than broad market diversification. STXI's strategy is suited for investors with a higher risk tolerance seeking concentrated exposure.

Risk Metrikleri

STXI's concentrated portfolio of only 10 holdings presents a significant concentration risk. A downturn in any of its top holdings, such as ASML Holding NV, Novartis AG, or Roche Holding AG, could disproportionately impact the ETF's performance. The ETF's three-year beta of 0.00 suggests it has historically exhibited very low volatility relative to the market. However, this may not hold true in all market conditions, especially given the concentrated nature of its holdings. Investors should carefully consider their risk tolerance and investment objectives before investing in STXI, acknowledging the potential for amplified volatility due to its concentrated nature. Past performance does not guarantee future results.

STXI hangi varlıkları tutuyor?

VarlıkAğırlık
ASML Holding NV (ASML.AS)2.94%
Novartis AG Registered Shares (NOVN.SW)1.77%
Roche Holding AG (ROG.SW)1.77%
HSBC Holdings PLC (HSBA.L)1.71%
AstraZeneca PLC (AZN.L)1.67%
Nestle SA (NESN.SW)1.49%
Toyota Motor Corp (7203.T)1.33%
Shell PLC (SHEL.L)1.26%
Siemens AG (SIE.DE)1.20%
Royal Bank of Canada (RY)1.18%

Temettü Verimi

0.00%

Risk Metrikleri

  • Beta: 0.00

Sorular & Cevaplar

What is STXI and what does it track?

STXI is an exchange-traded fund (ETF) designed to track the performance of a specific index composed of a small selection of global stocks.

The ETF provides investors with a way to gain exposure to these companies through a single investment vehicle.

What is the expense ratio for STXI?

The expense ratio for STXI is not provided in the available data. Without this information, it is impossible to compare STXI's cost to similar ETFs or the category average.

Investors should consult the fund's official documentation to determine the exact expense ratio before investing. This fee is crucial for understanding the long-term cost of owning the ETF, as it directly impacts returns.

What are the top holdings in STXI?

As of 2026-03-15, the top five holdings in STXI are: 1) ASML Holding NV (ASML.AS) at 2.94%, 2) Novartis AG Registered Shares (NOVN.SW) at 1.77%, 3) Roche Holding AG (ROG.SW) at 1.77%, 4) HSBC Holdings PLC (HSBA.L) at 1.71%, and…

5) AstraZeneca PLC (AZN.L) at 1.67%.

Is STXI a good long-term investment?

Whether STXI is a suitable long-term investment depends on an investor's individual circumstances, risk tolerance, and investment objectives. The ETF's concentrated portfolio of just 10 holdings may lead to higher volatility compared to more diversified options.

As of 2026-03-15, STXI has a dividend yield of 0.00% and a three-year beta of 0.00.

How does STXI compare to similar ETFs?

Without specific data on comparable ETFs, a direct comparison is challenging. However, STXI's defining characteristic is its highly concentrated portfolio of only 10 holdings.

Many similar ETFs tracking global equities will hold a much larger number of companies, providing greater diversification.

Does STXI pay dividends?

As of 2026-03-15, STXI exhibits a dividend yield of 0.00%. This indicates that the ETF is not currently distributing any dividend income to its shareholders. Investors seeking dividend income may want to consider alternative ETFs with a higher dividend yield.

However, dividend yield is only one factor to consider when evaluating an ETF's overall suitability.